Macroaggregation of Platelets in Plasma, as Distinct from Microaggregation in Whole Blood (and Plasma), as Determined Using Optical Aggregometry and Platelet Counting respectively, is Specifically Impaired following Cardiopulmonary Bypass in Man

Summary

We determined changes in platelet aggregability following cardiopulmonary bypass, using optical aggregometry to assess macroaggregation in platelet-rich plasma (PRP), and platelet counting to assess microaggregation both in whole blood and PRP. Hirudin was used as the anticoagulant to maintain normocalcaemia.

Microaggregation (%, median and interquartile range) in blood stirred with collagen (0.6 µg/ml) was only marginally impaired following bypass (91 [88, 93] at 10 min postbypass v 95 (92, 96] prebypass; n = 22), whereas macroaggregation (amplitude of response; cm) in PRP stirred with collagen (1.0µg/ml) was markedly impaired (9.5 [8.0, 10.8], n = 41 v 13.4 [12.7,14.3], n = 10; p <0.0001). However, in PRP, despite impairment of macroaggregation (9.1 [8.5, 10.1], n = 12), microaggregation was near-maximal (93 [91, 94]), as in whole blood stirred with collagen. In contrast, in aspirin-treated patients (n = 14), both collagen-induced microaggregation in whole blood (49 [47, 52]) and macroaggregation in PRP (5.1 [3.8, 6.6]) were more markedly impaired, compared with control (both p <0.001).

Similarly, in PRP, macroaggregation with ristocetin (1.5 mg/ml) was also impaired following bypass (9.4 [7.2, 10.7], n = 38 v 12.4 [10.0, 13.4]; p <0.0002, n = 20), but as found with collagen, despite impairment of macroaggregation (7.2 [3.5,10.9], n = 12), microaggregation was again near-maximal (96 [93,97]). The response to ristocetin was more markedly impared after bypass in succinylated gelatin (Gelo-fusine) treated patients (5.6 [2.8, 8.6], n = 17; p <0.005 v control), whereas the response to collagen was little different (9.3 v 9.5). In contrast to findings with collagen in aspirin-treated patients, the response to ristocetin was little different to that in controls (8.0 v 8.3). Impairment of macroaggregation with collagen or ristocetin did not correlate with the duration of bypass or the platelet count, indicating that haemodilution is not a contributory factor.

In conclusion: (1) Macroaggregation in PRP, as determined using optical aggregometry, is specifically impaired following bypass, and this probably reflects impairment of the build-up of small aggregates into larger aggregates. (2) Impairment of aggregate growth and consolidation could contribute to the haemostatic defect following cardiac surgery.

• References

• 1 Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-1697
• 2 Khuri SF, Wolfe JA, Josa M, Axford TC, Szymankski J, Assousa S, Ragno G, Patel M, Silverman A, Park M, Valeri CR. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovas Surg 1992; 104: 94-107
• 3 Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective a-granule release. Blood 1980; 56: 824-834
• 4 Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspumer H, Wolner E. Blood platelets in cardiopulmonary bypass operations: Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989; 97: 379-388
• 5 Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Capri-ni JA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59: 62-67
• 6 Zilla P, Fasol R, Deutsch M, Laufer G, Wollenek G, Mülller MM, Knöbl P, Vukovich T, Hammerle A, von Oppell U. Whole blood aggregometry and platelet adenine nucleotides during cardiac surgery. Scand J Cardiovasc Surg 1988; 22: 165-169
• 7 Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birji-niuk J, Ouimet H, Pasche B, Nelson MJ, Benoit SE, Rodino LJ, Barnard MR, Michelson AD. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107-117
• 8 Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiol 1991; 75: 388-393
• 9 Orchard MA, Goodchild CS, Prentice CRM, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, Michelson AD. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533-541
• 10 Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A₂ causes feedback amplification involving extensive thromboxane A₂ formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-641
• 11 Falcon CR, Cattaneo M, Ghidoni A, Mannucci PM. The in vitro production of thromboxane B₂ by platelets of diabetic patients is normal at physiological concentrations of calcium. Thromb Haemost 1993; 70: 389-392
• 12 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of the concentration of Ca²⁺ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989; 62: 968-976
• 13 Lages B, Weiss HJ. Dependence of human platelet functional responses on divalent cations: Aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemost 1981; 45: 173-179
• 14 John LCH, Rees GM, Kovacs IB. Inhibition of platelet function by heparin: An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993; 105: 816-822
• 15 Kirchmaier CM, Bellinger OK, Schulz B, Breddin HK. Effect of recombinant hirudin on cytosolic Ca²⁺ concentrations using different platelet stimulators. Haemostasis 1991; 21 (Suppl. 01) 121-126
• 16 Glusa E. Platelet aggregation in recombinant-hirudin-anticoagulated blood. Haemostasis 1991; 21 (Suppl. 01) 116-120
• 17 Falcon C, Amout J, Vermylen J. Platelet aggregation in whole blood-stu-dies with a platelet counting technique - methodological aspects and some applications. Thromb Haemost 1989; 61: 423-428
• 18 Pedvis LG, Wong T, Frojmovic MM. Differential inhibition of the platelet activation sequence: Shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost). Thromb Haemost 1988; 59: 323-328
• 19 Born GVR, Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 1967; 215: 1027-1029
• 20 Menys VC. Inhibition of collagen-induced human platelet activation in citrated whole blood by ICI D1542, a thromboxane A₂ synthase inhibitor and cyclic endoperoxide/thromboxane A₂ receptor antagonist. Platelets 1992; 3: 331-335
• 21 Frojmovic MM, Milton JG, Gear ARL. Platelet aggregation measured in vitro by microscopic and electronic particle counting. Methods in Enzy-mology 1989; 169: 134-149
• 22 Nieuwenhuis HK, Sixma JJ. Bleeding time measurements. In: Measurements of platelet function Harker LA, Zimmerman TS. (eds) Edinburgh; Churchill Livingstone: 1983: 26-49
• 23 Menys VC. Collagen induced human platelet aggregation: serotonin receptor antagonism retards aggregate growth in vitro. Cardiovasc Res 1993; 27: 1916-1919
• 24 Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 924-926
• 25 Saniabadi AR, Lowe GDO, Madhok R, Spowart K, Shaw B, Barbenel JC, Forbes CD. Red blood cells mediate spontaneous aggregation of platelets in whole blood. Atherosclerosis 1987; 66: 175-180
• 26 Brown P, Harrison MJG. The role of red blood cells in platelet aggregation in whole blood (letter). Atherosclerosis 1988; 71: 261-262
• 27 Saniabadi AR, Lowe GDO, Barbenel JC, Forbes CD. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225-232
• 28 Kuitunen A, Hynynen M, Salmenperä M, Rasi V, Järvinen A, Scheinin M, Neuvonen PJ, Fyhrquist F. Anaesthesia affects plasma concentrations of vasopressin, von Willebrand factor and coagulation factor VIII in cardiac surgical patients. Br J Anaesth 1993; 70: 173-180
• 29 Grant JA, Scrutton MC. Positive interaction between agonists in the aggregation response of human blood platelets: Interaction between ADP, adrenaline and vasopressin. Br J Haematol 1980; 44: 109-125
• 30 Butler J, Pillai R, Rocker GM, Westaby S, Parker D, Shale DJ. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg 1993; 105: 25-30
• 31 Valles J, Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ull-man HL, Aznar J. Downregulation of human platelet reactivity by neutrophils. J Clin Invest 1993; 92: 1357-1365
• 32 de Gaetano G, Evangelista V, Rajtar G, Del Maschio A, Cerletti C. Activated polymorphonuclear leukocytes stimulate platelet function. Thromb Res 1990; 25 (Suppl. 11) 25-32
• 33 Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. In: Measurements of platelet function Harker LA, Zimmerman TS. (eds) Edinburgh; Churchill Livingstone: 1983: 64-91
• 34 Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur RH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-797
• 35 Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793
• 36 Hardisty RM, Caen JP. Disorders of platelet function. In: Haemostasis and Thrombosis Bloom AL, Thomas DP. (eds) Edinburgh; Churchill Livingstone: 1987: 365-392